Lv5
970 积分 2024-09-01 加入
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
3天前
已完结
PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma
12天前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
12天前
已完结
Recent advances in oncolytic virus therapy for hepatocellular carcinoma
12天前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
13天前
已完结
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
13天前
已完结
Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
13天前
已完结
Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China
14天前
已关闭
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
14天前
已完结
Epigenetic enhancement of adoptive T cell immunotherapy
14天前
已完结
皖公网安备34019202002308
